Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · IEX Real-Time Price · USD
2.180
+0.040 (1.87%)
At close: Jul 19, 2024, 4:30 PM
2.150
-0.030 (-1.38%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Corvus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for CRVS stock have an average target of 5.75, with a low estimate of 3.50 and a high estimate of 8.00. The average target predicts an increase of 163.76% from the current stock price of 2.18.
Analyst Consensus: Buy
* Price targets were last updated on May 7, 2024.
Analyst Ratings
The average analyst rating for CRVS stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 5 | 5 | 5 | 5 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | +266.97% | May 7, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 1, 2024 |
| Mizuho | Mizuho | Hold Maintains $3.5 | Hold | Maintains | $3.5 | +60.55% | Mar 27, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $8 → $7 | Buy | Maintains | $8 → $7 | +221.10% | Mar 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $4 | Buy | Reiterates | $4 | +83.49% | Sep 7, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.49
from -0.56
EPS Next Year
-0.54
from -0.49
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 21.1M | 84.7M | 163.9M |
| Avg | n/a | n/a | 10.3M | 37.0M | 81.7M |
| Low | n/a | n/a | n/a | 10.3M | 35.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 726.6% | 343.1% |
| Avg | - | - | - | 260.9% | 120.8% |
| Low | - | - | - | 0.8% | -3.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.41 | -0.40 | -0.39 | -0.35 | 0.02 |
| Avg | -0.49 | -0.54 | -0.58 | -0.54 | -0.26 |
| Low | -0.54 | -0.74 | -0.77 | -0.67 | -0.50 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.